BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32642869)

  • 1. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas.
    Sievers P; Hielscher T; Schrimpf D; Stichel D; Reuss DE; Berghoff AS; Neidert MC; Wirsching HG; Mawrin C; Ketter R; Paulus W; Reifenberger G; Lamszus K; Westphal M; Etminan N; Ratliff M; Herold-Mende C; Pfister SM; Jones DTW; Weller M; Harter PN; Wick W; Preusser M; von Deimling A; Sahm F
    Acta Neuropathol; 2020 Sep; 140(3):409-413. PubMed ID: 32642869
    [No Abstract]   [Full Text] [Related]  

  • 2. Loss of p16 expression is a sensitive marker of CDKN2A homozygous deletion in malignant meningiomas.
    Tang V; Lu R; Mirchia K; Van Ziffle J; Devine P; Lee J; Phillips JJ; Perry A; Raleigh DR; Lucas CG; Solomon DA
    Acta Neuropathol; 2023 Apr; 145(4):497-500. PubMed ID: 36723772
    [No Abstract]   [Full Text] [Related]  

  • 3. p16 Immunohistochemistry as a Screening Tool for Homozygous CDKN2A Deletions in CNS Tumors.
    Zschernack V; Andreiuolo F; Dörner E; Wiedey A; Jünger ST; Friker LL; Maruccia R; Pietsch T
    Am J Surg Pathol; 2024 Jan; 48(1):46-53. PubMed ID: 37947008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for CDKN2A homozygous deletion in brain tumors].
    Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
    Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
    [No Abstract]   [Full Text] [Related]  

  • 5. CDKN2A/B deletions are strongly associated with meningioma progression: a meta-analysis of individual patient data.
    Wach J; Basaran AE; Arlt F; Vychopen M; Seidel C; Barrantes-Freer A; Müller W; Gaunitz F; Güresir E
    Acta Neuropathol Commun; 2023 Nov; 11(1):189. PubMed ID: 38017560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FISH analysis reveals CDKN2A and IFNA14 co-deletion is heterogeneous and is a prominent feature of glioblastoma.
    Al Shboul S; Boyle S; Singh A; Saleh T; Alrjoub M; Abu Al Karsaneh O; Mryyian A; Dawoud R; Gul S; Abu Baker S; Ball K; Hupp T; Brennan PM
    Brain Tumor Pathol; 2024 Jan; 41(1):4-17. PubMed ID: 38097874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical Statistics Unlock the Gateway to Further Research: Using Deep Learning to Predict CDKN2A/B Homozygous Deletion in Isocitrate Dehydrogenase-Mutant Astrocytoma.
    Takahashi K; Usuzaki T; Inamori R
    Korean J Radiol; 2023 Dec; 24(12):1303-1305. PubMed ID: 38016690
    [No Abstract]   [Full Text] [Related]  

  • 8. Response to "Medical Statistics Unlock the Gateway to Further Research: Using Deep Learning to Predict CDKN2A/B Homozygous Deletion in Isocitrate Dehydrogenase-Mutant Astrocytoma".
    Park YW; Han K; Kim SH
    Korean J Radiol; 2023 Dec; 24(12):1306-1308. PubMed ID: 38016689
    [No Abstract]   [Full Text] [Related]  

  • 9. Miniaturized handheld confocal microscopy identifies focal brain invasion in a mouse model of aggressive meningioma.
    Peyre M; Clermont-Taranchon E; Stemmer-Rachamimov A; Kalamarides M
    Brain Pathol; 2013 Jul; 23(4):371-7. PubMed ID: 23356716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene transcript fusions are associated with clinical outcomes and molecular groups of meningiomas.
    Zakimi N; Nguyen MP; Raleigh DR
    Acta Neuropathol; 2024 Mar; 147(1):57. PubMed ID: 38509407
    [No Abstract]   [Full Text] [Related]  

  • 11. Aggressive human MenG C meningiomas have a molecular counterpart in canines.
    Harmanci AS; Boudreau B; Lau S; Hosseingholi Nouri S; Mandel JJ; Lu HC; Harmanci AO; Klisch TJ; Levine JM; Patel AJ
    Acta Neuropathol; 2024 Feb; 147(1):42. PubMed ID: 38376654
    [No Abstract]   [Full Text] [Related]  

  • 12. Meningioma risk stratification with a targeted gene-expression biomarker.
    Nat Med; 2023 Dec; 29(12):3020-3021. PubMed ID: 38057502
    [No Abstract]   [Full Text] [Related]  

  • 13. Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes.
    Kessler T; Berberich A; Sadik A; Sahm F; Gorlia T; Meisner C; Hoffmann DC; Wick A; Kickingereder P; Rübmann P; Bendszus M; Opitz C; Weller M; van den Bent M; Stupp R; Winkler F; Brandes A; von Deimling A; Platten M; Wick W
    Cancer Med; 2020 Nov; 9(22):8373-8385. PubMed ID: 32991787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infratentorial IDH-mutant astrocytoma is a distinct subtype.
    Banan R; Stichel D; Bleck A; Hong B; Lehmann U; Suwala A; Reinhardt A; Schrimpf D; Buslei R; Stadelmann C; Ehlert K; Prinz M; Acker T; Schittenhelm J; Kaul D; Schweizer L; Capper D; Harter PN; Etminan N; Jones DTW; Pfister SM; Herold-Mende C; Wick W; Sahm F; von Deimling A; Hartmann C; Reuss DE
    Acta Neuropathol; 2020 Oct; 140(4):569-581. PubMed ID: 32776277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular alterations in meningioma: prognostic and therapeutic perspectives.
    Birzu C; Peyre M; Sahm F
    Curr Opin Oncol; 2020 Nov; 32(6):613-622. PubMed ID: 32890025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1.
    Sievers P; Sill M; Blume C; Tauziede-Espariat A; Schrimpf D; Stichel D; Reuss DE; Dogan H; Hartmann C; Mawrin C; Hasselblatt M; Stummer W; Schick U; Hench J; Frank S; Ketter R; Schweizer L; Schittenhelm J; Puget S; Brandner S; Jaunmuktane Z; Küsters B; Abdullaev Z; Pekmezci M; Snuderl M; Ratliff M; Herold-Mende C; Unterberg A; Aldape K; Ellison DW; Wesseling P; Reifenberger G; Wick W; Perry A; Varlet P; Pfister SM; Jones DTW; von Deimling A; Sahm F;
    Acta Neuropathol; 2021 Feb; 141(2):281-290. PubMed ID: 33319313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood.
    Weller M; van den Bent M; Preusser M; Le Rhun E; Tonn JC; Minniti G; Bendszus M; Balana C; Chinot O; Dirven L; French P; Hegi ME; Jakola AS; Platten M; Roth P; Rudà R; Short S; Smits M; Taphoorn MJB; von Deimling A; Westphal M; Soffietti R; Reifenberger G; Wick W
    Nat Rev Clin Oncol; 2021 Mar; 18(3):170-186. PubMed ID: 33293629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary.
    Louis DN; Perry A; Wesseling P; Brat DJ; Cree IA; Figarella-Branger D; Hawkins C; Ng HK; Pfister SM; Reifenberger G; Soffietti R; von Deimling A; Ellison DW
    Neuro Oncol; 2021 Aug; 23(8):1231-1251. PubMed ID: 34185076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model.
    Feinauer MJ; Schneider SW; Berghoff AS; Robador JR; Tehranian C; Karreman MA; Venkataramani V; Solecki G; Grosch JK; Gunkel K; Kovalchuk B; Mayer FT; Fischer M; Breckwoldt MO; Brune M; Schwab Y; Wick W; Bauer AT; Winkler F
    Blood; 2021 Mar; 137(9):1219-1232. PubMed ID: 33270819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up.
    Roth P; Pace A; Le Rhun E; Weller M; Ay C; Cohen-Jonathan Moyal E; Coomans M; Giusti R; Jordan K; Nishikawa R; Winkler F; Hong JT; Ruda R; Villà S; Taphoorn MJB; Wick W; Preusser M; ;
    Ann Oncol; 2021 Feb; 32(2):171-182. PubMed ID: 33246022
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.